International Journal of Thyroidology

Table. 5.

Table. 5.

Data sources in economic evaluation studies of clinical outcomes for thyroid cancer

Type of outcomes CA N (%) CMA N (%) CEA N (%) CUA N (%)
Clinical outcomes
Non-SR-based literature review - - 5 (83.3) 26 (74.3)
Clinical trial - - - 5 (14.3)
Prospective or retrospective cohort - 1 (12.5) 1 (16.7) 1 (2.9)
Not certified 5 (100.0) 7 (87.5) - 3 (8.6)
Total 5 (100.0) 8 (100.0) 6 (100.0) 35 (100.0)
Non-clinical outcomes
Non-SR-based literature review - 1 (11.1) 4 (44.4) 26 (78.8)
Medicare reimbursement 4 (66.7) 6 (66.7) 3 (33.3) -
Raw dataa 1 (16.7) 2 (22.2) 2 (22.2) 5 (15.2)
Expert opinions - - - 1 (3)
Not certified 1 (16.7) - - 1 (3)
Total 6 (100.0)b 9 (100.0)b 9 (100.0)b 33 (100.0)b

CA: cost analysis, CEA: cost-effectiveness analysis, CMA: cost-minimization analysis, CUA: cost-utility analysis, N: number, SR: systematic review

aClinical trial, registry, or single hospital data.

bTotal number exceeds the number of studies owing to studies having more than one data source.

Int J Thyroidol 2022;15:74-104 https://doi.org/10.11106/ijt.2022.15.2.74
© 2022 Int J Thyroidol